Pharmacokinetics of intravenous voriconazole in obese patients: Implications of CYP2C19 homozygous poor metabolizer genotype

Pharmacotherapy

Volumn 33, Issue 3, 2013, Pages

  Moriyama, Brad ^a   Jarosinski, Paul F ^a   Figg, William D ^b   Henning, Stacey A ^a   Danner, Robert L ^a   Penzak, Scott R ^a   Wayne, Alan S ^b   Walsh, Thomas J ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Cornell University ^*  (United States)

Author keywords

CYP2C19; Genotype; Intravenous; Obese; Pharmacokinetics; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ASPERGILLOSIS; BODY MASS; CASE REPORT; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; GENOTYPE; HISPANIC; HOMOZYGOSITY; HUMAN; LIQUID CHROMATOGRAPHY; LUNG NODULE; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; OBESITY; QT PROLONGATION; REVIEW; SIDE EFFECT;

ADOLESCENT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASPERGILLOSIS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GENOTYPE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OBESITY; PYRIMIDINES; TRIAZOLES;

EID: 84875423644     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1192     Document Type: Review

References (16)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012;307:483-90.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
3. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007;27:1081-91.
4. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 2011;55:2601-5.
5. Dickmeyer NJ, Kiel PJ. Dosing voriconazole in an obese patient. Clin Infect Dis 2011;53:745. (letter).
6. Davies-Vorbrodt S, Ito J, Dadwal S, Kriengkauykiat J. Voriconazole (VC) serum levels in obese immunocompromised patients (Pts). Presented at: Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 19, 2011. (Abstract A1-1154).
7. Moriyama B, Falade-Nwulia O, Leung J, et al. Prolonged halflife of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. Mycoses 2011;54:e877-9. (letter).
8. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008;30:167-72.
9. Lee S, Kim BH, Nam WS, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 2012;52:195-203.
10. Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother 2009;43:726-31.
11. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009;49:196-204.
12. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011;12:861-72.
13. De Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 2006;10:135-51.
14. Meletiadis J, Chanock S, Walsh TJ. Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics 2008;9:561-84.
15. Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012;55:381-90.
16. Andes D, Lepak A. Editorial commentary: antifungal therapeutic drug monitoring progress: getting it right the first time. Clin Infect Dis 2012;55:391-3.